PDPiet Dirix

Piet Dirix

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Piet Dirix has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiotherapy for laryngeal squamous cell carcinoma: current standards

    by Piet Dirix, Maarten Lambrecht, Sandra Nuyts

    During the past decades, treatment of laryngeal cancer has changed substantially, mainly due to the advent of novel approaches such as combined modality therapy as well as improvements in radiotherapeutic techniques. Locoregionally advanced disease in particular, which resulted in high recurrence and mortality rates, is now associated with long-term disease-free survival in a large proportion of cases. Moreover, with multimodality treatment, larynx preservation is now possible in most patients. There are varied regimens in use for patients with advanced disease, but at the same time the multitude of options can plague the clinician when trying to select the most appropriate one. This article will attempt to put the various approaches into perspective.


  • Post-operative intensity-modulated radiotherapy for malignancies of the nasal cavity and paranasal sinuses

    by Piet Dirix, Sandra Nuyts, Bianca Vanstraelen, An Nulens, Robert Hermans, Mark Jorissen, Vincent Vander Poorten, Walter Van Den Bogaert


  • Radiation‐induced xerostomia in patients with head and neck cancer

    by Piet Dirix, Sandra Nuyts, Walter Van Den Bogaert

    A dry mouth or xerostomia is one of the most common complications during and after radiotherapy for head and neck cancer, because irreparable damage is caused to the salivary glands, which are included in the radiation fields. Xerostomia not only significantly impairs the quality of life of potentially cured cancer patients, it may also lead to severe and long‐term oral disorders. Because management of xerostomia is rarely effective, prevention is paramount. Several strategies have been developed to avoid radiation‐induced salivary dysfunction without compromising definitive oncologic treatment. These include salivary gland‐sparing radiation techniques, such as 3‐dimensional conformal or intensity‐modulated radiotherapy, concomitant cytoprotectants, and surgical salivary gland transfer. However, these preventive approaches are not applicable to all patients, and comprehensive scientific research that incorporates new biological insights is warranted to optimize the therapeutic index of radiotherapy for head and neck cancer. Cancer 2006. © 2006 American Cancer Society.